Todo S, Tzakis A G, Abu-Elmagd K, Reyes J, Nakamura K, Casavilla A, Selby R, Nour B M, Wright H, Fung J J
Department of Surgery, University of Pittsburgh School of Medicine, Pennsylvania.
Ann Surg. 1992 Sep;216(3):223-33; discussion 233-4. doi: 10.1097/00000658-199209000-00002.
Under FK 506-based immunosuppression, the entire cadaver small bowel except for a few proximal and distal centimeters was translated to 17 randomly matched patients, of whom two had antigraft cytotoxic antibodies (positive cross-match). Eight patients received the intestine only, eight had intestine in continuity with the liver, and one received a full multivisceral graft that included the liver, stomach, and pancreas. One liver-intestine recipient died after an intestinal anastomotic leak, sepsis, and graft-versus-host disease. The other 16 patients are alive after 1 to 23 months, in one case after chronic rejection, graft removal, and retransplantation. Twelve of the patients have been liberated from total parenteral nutrition, including all whose transplantation was 2 months or longer ago. The grafts have supported good nutrition, and in children, have allowed growth and weight gain. Management of these patients has been difficult and often complicated, but the end result has been satisfactory in most cases, justifying further clinical trials. The convalescence of the eight patients receiving intestine only has been faster and more trouble free than after liver-intestine or multivisceral transplantation, with no greater difficulty in the control of rejection.
在基于FK 506的免疫抑制治疗下,将除了近端和远端几厘米之外的整个尸体小肠移植给17名随机匹配的患者,其中两名患者有抗移植物细胞毒性抗体(交叉配型阳性)。8名患者仅接受了小肠移植,8名患者接受了与肝脏相连的小肠移植,1名患者接受了包括肝脏、胃和胰腺的全多脏器移植。一名肝肠联合移植受者在发生肠吻合口漏、败血症和移植物抗宿主病后死亡。其他16名患者在1至23个月后存活,其中1例在经历慢性排斥反应、移除移植物并再次移植后存活。12名患者已摆脱了全胃肠外营养,包括所有移植时间在2个月或更久之前的患者。移植物维持了良好的营养状况,对于儿童患者,还促进了生长和体重增加。这些患者的管理一直很困难且常常很复杂,但大多数情况下最终结果令人满意,值得进一步开展临床试验。仅接受小肠移植的8名患者的康复过程比接受肝肠联合移植或多脏器移植后的康复过程更快且问题更少,在控制排斥反应方面也没有更大的困难。